Consideration of Costs and Open-Label Studies of Erenumab-Reply

JAMA Neurol. 2019 Feb 1;76(2):236-237. doi: 10.1001/jamaneurol.2018.4141.

Authors

Elizabeth W Loder¹, Rebecca C Burch¹

Affiliation

¹ Division of Headache, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

PMID: 30575855
DOI: 10.1001/jamaneurol.2018.4141

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal*
Antibodies, Monoclonal, Humanized
Calcitonin Gene-Related Peptide Receptor Antagonists
Humans
Migraine Disorders*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Calcitonin Gene-Related Peptide Receptor Antagonists
erenumab